Evaluation of the polypill therapy effectiveness in patients with arterial hypertension and dyslipidemia who underwent COVID-19

Abstract

Background. To study the dynamics of blood pressure (BP), lipid profile and arterial stiffness after 12 weeks of polypill therapy, including perindopril, indapamide and rosuvastatin. Materials and methods. 40 patients with arterial hypertension (AH) and dyslipidemia who underwent COVID-19 were included. 35 persons (87.5%) completed the follow-up period. All patients had their office blood pressure measured using the Korotkov method. A biochemical blood test was performed to determine total cholesterol, highdensity lipoproteins (HDL), triglycerides (TG). The level of low-density lipoprotein cholesterol (LDL) was calculated. With the applanation tonometry, systolic (SDao), diastolic (DDao) and pulse (PDao) pressure in the aorta, carotid-femoral pulse wave velocity (PWVcf) were recorded. Results. Against the background of polypill therapy, a decrease in systolic blood pressure by 18% and diastolic blood pressure by 17% was noted for 12 weeks. The target BP (<140 and 90 mmHg) were achieved in 30 patients (85.7%) after 4 weeks of treatment, and in 34 patients (97.1%) after 12 weeks. There was also a decrease in OS by 39.6%, TG – by 27.7%, LDL cholesterol – by 51.2%. The target levels of LDL cholesterol were reached by 23 patients (65.7%). According to the data of applanation tonometry, a significant decrease in the indicators of central hemodynamics was recorded: SDao – by 17,5%, DDao – by 12,9%, PDao – by 17,6%, as well as a decrease in PWVcf by 10,1%. Conclusions. Taking polypill therapy for 12 weeks demonstrated a significant improvement in the parameters of the lipid profile, a decrease in office and central blood pressure.

Keywords

• arterial hypertension
• arterial pressure
• arterial stiffness
• lipid profile
• polypill therapy
• covid-19